Europe/Sponsors
From 2013.igem.org
(Difference between revisions)
(7 intermediate revisions not shown) | |||
Line 7: | Line 7: | ||
<li><font size="5"><b>iGEM 2013 Europe Platinum Partners</b></font></li> | <li><font size="5"><b>iGEM 2013 Europe Platinum Partners</b></font></li> | ||
<br/><br/> | <br/><br/> | ||
- | <A href="http://www.biomerieux.com/" title=" | + | <table> |
- | + | <tr> | |
- | + | <td><A href="http://www.biomerieux.com/" title="bioMérieux"><IMG Align="left" src="https://static.igem.org/mediawiki/2013/5/56/EXE-LOGO-VA.jpg" style="margin-right:50px;" border="0" alt="bioMérieux" width="430" /></A></td> | |
+ | |||
+ | <td><p style="line-height:15px;"><b><i>Pioneering Diagnostics</b></i><br/> | ||
+ | A world leader in the field of <i><b>in vitro</i> diagnostics</b> for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors.<br/> | ||
+ | With more than 7,400 employees in the world, bioMérieux provides diagnostic solutions (reagents, instruments, software and services) which determine the source of disease and contamination to <b>improve patient health</b> and <b>ensure consumer safety</b>. | ||
+ | <ul> | ||
+ | <li style="line-height:15px;">Its products are used for diagnosing <b>infectious diseases</b> (HIV, hepatitis, tuberculosis, etc.) and providing high medical value results for <b>cancer</b> screening and monitoring and <b>cardiovascular emergencies</b>.</li> | ||
+ | <li style="line-height:15px;">They are also used for detecting microorganisms in <b>agri-food, pharmaceutical and cosmetic products</b>.</li> | ||
+ | </ul> | ||
+ | <b><i>What are in vitro diagnostics?</b></i> | ||
<ul> | <ul> | ||
- | <li> | + | <li style="line-height:15px;">Analyzing a biological sample to detect and measure the presence of disease-causing agents (bacteria, viruses,…) or substances produced by the body.</li> |
- | + | • Essential first step before any clinical diagnosis. | |
- | <li> | + | |
+ | <li style="line-height:15px;">Analyzing a food, drug or air sample to monitor and confirm the quality of the production process.</li> | ||
+ | • Necessary to ensure safety in food as well as in pharmaceutical and cosmetic products. | ||
- | |||
</ul> | </ul> | ||
- | < | + | </td> |
+ | </tr> | ||
+ | </table> | ||
+ | </p> | ||
+ | |||
<br/> | <br/> | ||
<br/> | <br/> | ||
Line 24: | Line 38: | ||
<li><font size="5"><b>iGEM 2013 Europe Gold Partners</b></font></li> | <li><font size="5"><b>iGEM 2013 Europe Gold Partners</b></font></li> | ||
<br/><br/> | <br/><br/> | ||
- | <A href="http://www.erasynbio.eu/" title="ERASynbio"><IMG Align="left" src="https://static.igem.org/mediawiki/2013/c/c2/Logo-erasynbio.jpg" style="margin-right:50px;" border="0" alt="ERASynbio" width=" | + | <table> |
+ | <tr> | ||
+ | <td width=50%><A href="http://www.erasynbio.eu/" title="ERASynbio"><IMG Align="left" src="https://static.igem.org/mediawiki/2013/c/c2/Logo-erasynbio.jpg" style="margin-right:50px;" border="0" alt="ERASynbio" width="400"/></A></td> | ||
+ | |||
+ | <td width=50%><p>The central idea of ERASynBio is <b>to promote the robust development of Synthetic Biology</b> by structuring and coordinating national efforts and investment. ERASynBio's main activities include developing a strategic research agenda / white paper, which supports the emergence of national Synthetic Biology programmes and lays the ground for transnational funding activities via joint calls in the project. ERASynBio stimulates and tackles the interdisciplinary nature and immaturity of the field by offering training and educational possibilities, establishing an interdisciplinary advisory board and inviting observers of other funding organisations. Tight <b>collaboration between academia and industry</b> aiming to fertilize the innovation process is occuring on several levels. To adhere to ethical, legal and societal aspects as well as to technical issues like standardisation and infrastructure development ERASynBio is tracing the ongoing work and research on these framework conditions, integrating them in its strategic documents and activities. </td> | ||
+ | |||
- | + | </tr> | |
+ | </table> | ||
<br/><br/> | <br/><br/> | ||
Latest revision as of 18:56, 6 September 2013
- iGEM 2013 Europe Platinum Partners
- iGEM 2013 Europe Gold Partners
- iGEM 2013 Europe Governmental Partners
- iGEM 2013 Europe Academic Partners